- Home
- IGC vs NTIP Comparison
IGC vs NTIP Comparison
Compare IGC & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- NTIP
- Stock Information
- Founded
- IGC 2005
- NTIP 1990
- Country
- IGC United States
- NTIP United States
- Employees
- IGC N/A
- NTIP N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- IGC Health Care
- NTIP Miscellaneous
- Exchange
- IGC Nasdaq
- NTIP Nasdaq
- Market Cap
- IGC 29.4M
- NTIP 32.9M
- IPO Year
- IGC N/A
- NTIP 1998
- Fundamental
- Price
- IGC $0.33
- NTIP $1.37
- Analyst Decision
- IGC Strong Buy
- NTIP
- Analyst Count
- IGC 2
- NTIP 0
- Target Price
- IGC $3.75
- NTIP N/A
- AVG Volume (30 Days)
- IGC 380.9K
- NTIP 25.3K
- Earning Date
- IGC 02-12-2025
- NTIP 03-07-2025
- Dividend Yield
- IGC N/A
- NTIP 7.30%
- EPS Growth
- IGC N/A
- NTIP N/A
- EPS
- IGC N/A
- NTIP N/A
- Revenue
- IGC $1,183,000.00
- NTIP $1,881,000.00
- Revenue This Year
- IGC N/A
- NTIP N/A
- Revenue Next Year
- IGC $13.38
- NTIP N/A
- P/E Ratio
- IGC N/A
- NTIP N/A
- Revenue Growth
- IGC N/A
- NTIP 129.39
- 52 Week Low
- IGC $0.27
- NTIP $1.22
- 52 Week High
- IGC $0.91
- NTIP $2.25
- Technical
- Relative Strength Index (RSI)
- IGC 41.18
- NTIP 49.93
- Support Level
- IGC $0.31
- NTIP $1.33
- Resistance Level
- IGC $0.37
- NTIP $1.41
- Average True Range (ATR)
- IGC 0.02
- NTIP 0.05
- MACD
- IGC -0.00
- NTIP -0.00
- Stochastic Oscillator
- IGC 28.17
- NTIP 33.33
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.